← Leaderboards
Mei Yee Koh
University Of Tx Md Anderson Can Ctr
$5,871,481
Attributed
$5,871,481
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $858.1K · FY2012–25$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,871,481 · 4
By mechanism
R01$5,785,618 · 3
R03$85,863 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroLinkHypoxiaResponseIn VivoTissuesTumor Suppressor ProteinsMediatingEtiologyGenetic TranscriptionSamplingPlayAutomobile DrivingTumorNeoplasm MetastasisBaseNovel StrategiesGenesRenal CarcinomaHypoxia Inducible FactorInhibitor/AntagonistRenal Cell CarcinomaSmall MoleculeTherapy Resistant
Grant awards (16)
A Role for the Novel HAF-NFkappaB Axis in Driving Obesity-Associated Liver Cancer$858,089
R01 · FY2025 · CA · contact PI
A Role for the Novel HAF-NFkappaB Axis in Driving Obesity-Associated Liver Cancer$409,784
R01 · FY2024 · CA · contact PI
A Role for the Novel HAF-NFkappaB Axis in Driving Obesity-Associated Liver Cancer$421,432
R01 · FY2023 · CA · contact PI
A Role for the Novel HAF-NFkappaB Axis in Driving Obesity-Associated Liver Cancer$442,372
R01 · FY2022 · CA · contact PI
A novel approach for the selective inhibition of HIF-2a in kidney cancer$336,943
R01 · FY2021 · CA · contact PI
A novel approach for the selective inhibition of HIF-2a in kidney cancer$336,943
R01 · FY2020 · CA · contact PI
A novel approach for the selective inhibition of HIF-2a in kidney cancer$326,834
R01 · FY2019 · CA · contact PI
A novel approach for the selective inhibition of HIF-2a in kidney cancer$336,943
R01 · FY2018 · CA · contact PI
The targeting of the HIF switch in kidney cancer$404,838
R01 · FY2017 · CA · contact PI
A novel approach for the selective inhibition of HIF-2a in kidney cancer$348,203
R01 · FY2017 · CA · contact PI
The targeting of the HIF switch in kidney cancer$521,079
R01 · FY2016 · CA · contact PI
The targeting of the HIF switch in kidney cancer$521,079
R01 · FY2015 · CA · contact PI
The targeting of the HIF switch in kidney cancer$521,079
R01 · FY2014 · CA · contact PI
High-throughput screen for specific small-molecule inhibitors of HIF-2A activity$42,413
R03 · FY2013 · DA · contact PI
High-throughput screen for specific small-molecule inhibitors of HIF-2A activity$3,950
R03 · FY2013 · DA · contact PI
High-throughput screen for specific small-molecule inhibitors of HIF-2A activity$39,500
R03 · FY2012 · DA · contact PI